Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: No clinical model exists to predict the occurrence of hepatocellular carcinoma in sustained virologic response-achieving (HCC after SVR) patients with chronic hepatitis C (CHC). Methods: We performed a case-control study using a clinical database to research the risk factors for HCC after SVR. A predictive model based on risk factors was established, and the area under the receiver operating characteristic curve (AUC) was calculated. Results: In the multivariate model, an initial diagnosis of compensated cirrhosis and post-SVR albumin reductions of 1 g/L were associated with 21.7-fold (95% CI, 4.2 to 112.3; p<0.001) and 1.3-fold (95% CI, 1.1 to 1.7; p=0.004) increases in the risk of HCC after SVR, respectively. A predictive model based on an initial diagnosis of compensated cirrhosis (yes, +1; no, 0) and post- SVR albumin ≤36.0 g/L (yes, +1; not, 0) predicted the occurrence of HCC after SVR with a cutoff value of >0, an AUC of 0.880, a sensitivity of 0.833, a specificity of 0.896, and a negative predictive value of 0.956. Conclusions: An initial diagnosis of compensated cirrhosis combined with a post-SVR albumin value of ≤36.0 g/L predicts the occurrence of HCC after SVR in patients with CHC.
Abstract
Background/Aims: No clinical model exists to predict the occurrence of hepatocellular carcinoma in sustained virologic response-achieving (HCC after SVR) patients with chronic hepatitis C (CHC). Methods: We performed a case-control study using a clinical database to research the risk factors for HCC after SVR. A predictive model based on risk factors was established, and the area under the receiver operating characteristic curve (AUC) was calculated. Results: In the multivariate model, an initial diagnosis of compensated cirrhosis and post-SVR albumin reductions of 1 g/L were associated with 21.7-fold (95% CI, 4.2 to 112.3; p<0.001) and 1.3-fold (95% CI, 1.1 to 1.7; p=0.004) increases in the risk of HCC after SVR, respectively. A predictive model based on an initial diagnosis of compensated cirrhosis (yes, +1; no, 0) and post- SVR albumin ≤36.0 g/L (yes, +1; not, 0) predicted the occurrence of HCC after SVR with a cutoff value of >0, an AUC of 0.880, a sensitivity of 0.833, a specificity of 0.896, and a negative predictive value of 0.956. Conclusions: An initial diagnosis of compensated cirrhosis combined with a post-SVR albumin value of ≤36.0 g/L predicts the occurrence of HCC after SVR in patients with CHC.
참고문헌 (23)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of hepatitis C virus infection", J Hepatol, 55, pp.245~264 (2011)
- Lavanchy D, "Evolving epidemiology of hepatitis C virus", Clin Microbiol Infect, 17, pp.107~115 (2011)
- Swain MG, "A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin", Gastroenterology, 139, pp.1593~1601 (2010)
- Sato A, "Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan", Intern Med, 52, pp.2701~2706 (2013)
- Morgan TR, "Outcome of sustained virological responders with histologically advanced chronic hepatitis C", Hepatology, 52, pp.833~844 (2010)
- Shiffman ML, "Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus", Oncology, 78(1), pp.11~16 (2010)
- Bruix J, "Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C", Gastroenterology, 140, pp.1990~1999 (2011)
- Dieperink E, "Allcause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C", Dig Dis Sci, 59, pp.872~880 (2014)
- Nagaoki Y, "Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy", J Gastroenterol, 46, pp.799~808 (2011)
- Asahina Y, "Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C", Hepatology, 58, pp.1253~1262 (2013)
- Loomba R, "Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study", Am J Epidemiol, 177, pp.333~342 (2013)
- Zeng QL, "Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study", World J Gastroenterol, 20, pp.5519~5526 (2014)
- Zakhari S, "Bermuda Triangle for the liver: alcohol, obesity, and viral hepatitis", J Gastroenterol Hepatol, 28(1), pp.18~25 (2013)
- Kita Y, "Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus", Metabolism, 56, pp.1682~1688 (2007)
- Giordanino C, "Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study", Dig Liver Dis, 44, pp.406~412 (2012)
- Tsubouchi N, "Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: a community-based cohort study", Hepatol Res, 43, pp.1130~1138 (2013)
- Fujita Y, "The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma", Br J Cancer, 94, pp.737~739 (2006)
- Pyong SJ, "Case-control study of hepatocellular carcinoma among Koreans living in Osaka, Japan", Jpn J Cancer Res, 85, pp.674~679 (1994)
- Asahina Y, "Reply: to PMID 23564522", Hepatology, 60, pp.764~ (2014)
- Toyoda H, "Postinterferon alpha-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results?", Hepatology, 60, pp.762~763 (2014)
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
- Tamaki N, "Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients", J Gastroenterol, 49, pp.1495~1503 (2014)